Criselle Angeline Peñamante

Criselle Angeline Peñamante

Auto-generated profile, based on publicly available information

Criselle Angeline Peñamante

Department of Clinical Epidemiology, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
OUOlivier Uwishema
Olivier Uwishema
OAOluyemisi Adekunbi
Oluyemisi Adekunbi
CPCriselle Angeline Peñamante
Criselle Angeline Peñamante
BBBezawit Kassahun Bekele
Bezawit Kassahun Bekele
CKCarlo Khoury
Carlo Khoury
Helen OnyeakaHelen Onyeaka
Helen Onyeaka
The Coronavirus Disease - 19 (COVID-19) pandemic has put additional strain on Africa's fragile healthcare systems and has impacted the rise of emerging and re-emerging infectious diseases. Currently, there is a rise in cases of Monkeypox Disease, a zoonotic viral disease caused by the Monkeypox virus, which was first documented in 1970 in the Democratic Republic of the Congo. Most of the clinical symptoms of Monkeypox resemble that of smallpox, whose virus also belongs to the same genus. Initial symptoms include headache, fever, and fatigue, followed by lymphadenopathy and a rash. This study aims to provide more insight into Monkeypox by exposing its current burden and efforts to combat it amidst COVID-19 in Africa. Since Monkeypox disease is re-emerging and is less contagious than COVID-19, prevention and treatment are much more manageable. Still, African countries face several crucial challenges in responding to the Monkeypox in times of the covid-19 pandemic. These include lack of a well-functioning surveillance system for early detection of the disease, lack of awareness and knowledge of the monkeypox disease across the general population, lack of healthcare facilities already burdened by COVID-19 cases, and shortage of trained healthcare professionals.

25 November 2023 in Tropical Diseases, Travel Medicine and Vaccines
Verified
Journal Article
Open access
PDF file
MEMohamed Elsaid
Mohamed Elsaid
Arvind NuneArvind Nune
Arvind Nune
ABAml Brakat
Aml Brakat
AAAyush Anand
Ayush Anand
MAMahmoud Alashwah
Mahmoud Alashwah
CPCriselle Angeline C. Peñamante
Criselle Angeline C. Peñamante
Background: The American Society of Haematology defines immune thrombocytopenic purpura (ITP) as a common hematologic disorder characterized by a transient or long-term decrease in platelet counts (< 100 × 109/L.), purpura, and haemorrhagic episodes caused by antiplatelet autoantibodies, with the exclusion of other clinical conditions. We aimed to systematically determine the incidence of ITP in adults and children following influenza vaccination, the duration between vaccination and the occurrence of ITP, and to identify predictors of ITP after the vaccine. Methods: We searched PubMed, Cochrane Library, Google Scholar, Web of Science, Scopus, and Science Direct. We included primary studies that assessed the occurrence of immune thrombocytopenia in individuals who had received any influenza vaccine (primary or booster dose), regardless of the dosage, preparation, time of administration, or age of the participants. We excluded studies that were (a) Narrative, scoping, and umbrella reviews ;(b) studies with no accessible full text, abstract-only studies, or (c) Overlapping or unreliable data. The risk of bias in the included studies was assessed using the Joanna Briggs Institute (JBI) tool. We categorized studies for qualitative analysis based on study design. Descriptive statistics were used to summarize quantitative data, including the incidence of ITP after influenza vaccination. Results: Out of 729 articles retrieved from the database search, we included 24 studies. All patients identified and included in this systematic review presented with immune thrombocytopenia, determined by their platelet count. The period between vaccination and the occurrence of ITP ranged from (2:35 days). The mean duration was 13.5 days. The analysis revealed a statistically significant incidence rate ratio (IRR) = 1.85,95% CI [1.03–3.32] of ITP occurrence after 42 days. Conclusions: Influenza-associated ITP is uncommon, self-limiting, non-life-threatening, and curable. None of the patients reported having severe adverse events or death. Further studies are required to confirm the exact incidence of the ITP to better understand the pathophysiology of ITP development post-influenza vaccination.

1 January 2023 in International Journal of Surgery
Verified
Journal Article
Open access
OUOlivier Uwishema
Olivier Uwishema
GNGoodluck Nchasi
Goodluck Nchasi
GNGlorian Goodluck Nnko
Glorian Goodluck Nnko
EMElias Mtawala
Elias Mtawala
DBDeusdedith Boniphace Bulimbe
Deusdedith Boniphace Bulimbe
CPCriselle Angeline Peñamante
Criselle Angeline Peñamante